A novel CD123xVdelta2 bispecific T cell engager induces potent and tumor selective Vgamma9Vdelta2-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome.
A new bispecific T-cell therapy selectively destroyed blood cancer cells in primates with milder inflammatory reactions than existing approaches, advancing toward human trials.
A humanized half-life-extended CD123xVdelta2 bispecific T-cell engager potently and selectively lysed patient-derived AML/MDS cells via Vgamma9Vdelta2 T cells with lower CRS cytokine induction than CD3-based bispecifics, demonstrated xenograft efficacy with antibody-like PK in primates, and prompted Phase 1 trial initiation (ACTRN12624001214527). This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Preclinical (in vitro + xenograft + NHP PK); Phase 1 trial initiated
- Category
- hematologic_malignancies
- Maturity
- Exploratory
- Journal
- Clin Immunol
Why it surfaced
Novel gamma-delta T cell-redirecting approach for AML/MDS combining reduced CRS risk with comprehensive preclinical validation including patient-derived cells; Phase 1 initiation signals translational readiness, highly relevant to hematologic malignancy immunotherapy pipeline.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.